EVOTEC SE INH O.N.
Commented by Stefan Feulner on March 20th, 2023 | 09:37 CET
Evotec, Defence Therapeutics, Morphosys - Movement in the biotech sector
Is a new wave of takeovers starting in the biotech sector? Already last year, acquisitions by Big Pharma were expected to increase, but these largely failed to materialize. However, this could accelerate in the current year. On the one hand, pharmaceutical companies, such as vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio; on the other hand, second-tier stocks are attractive targets due to the strong correction.Read
Commented by Fabian Lorenz on March 16th, 2023 | 11:51 CET
Takeover speculation at Defence Therapeutics! What are BioNTech, Morphosys, and Evotec doing?
Defence Therapeutics is one of the biotech high flyers of the past months. The share has more than doubled since October. And this could be just the beginning. Operationally, things are going well, a strong partner has been acquired, and experts are speculating about a takeover. And what are the German biotechs doing? At BioNTech, it will be exciting at the end of March, because the Mainz-based company needs new blockbusters. At Morphosys, analysts recently saw further downside potential. Will a new management board bring about a turnaround? Evotec also had little positive to report. However, an AI investment in the hype surrounding ChatGPT is making headlines.Read
Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET
Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics
Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.Read
Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET
Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions
Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.Read
Commented by Stefan Feulner on November 21st, 2022 | 11:07 CET
Morphosys, Defence Therapeutics, Evotec - Stabilization after the sell-off
After the publication of the figures for the third quarter, many biotech companies were able to surprise positively. Due to the partly panic-like sell-off in this capital-intensive sector, there are attractive entry opportunities at a strongly discounted level, which should pay off with disproportionate price gains in the long term. The fact that promising companies are already trading below their cash levels shows that the panic is exaggerated. There are currently signs of a bottoming out, which could herald the next upward wave.Read
Commented by Stefan Feulner on October 26th, 2022 | 11:28 CEST
Biogen, Cardiol Therapeutics, Evotec - Brilliant results
The reporting season for the third quarter is in full swing and is creating a thoroughly positive mood. For example, the software group SAP posted surprisingly strong growth in its cloud business in the third quarter, and its operating result was better than forecast. Positive signals are also coming from the biotech sector, which has been badly battered in recent months. After the horrendous share price losses, this sector, in particular, offers attractive long-term entry levels.Read
Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST
Evotec, Defence Therapeutics, Formycon - Biotech opportunity!
Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.Read
Commented by Stefan Feulner on June 16th, 2022 | 11:01 CEST
Biotech stocks ahead of the turnaround - Evotec, NervGen and MorphoSys
Biotechnology stocks could not escape the current correction. The broad-based NASDAQ Biotechnology Index, for example, has lost around 40% since its peak last August. The fact that biotechnology will increasingly become a key technology in the future was already demonstrated during the Corona pandemic when tests, vaccines and drugs were developed in a very short time and made available in large quantities. Thus, more and more capital is likely to move into the sector in the coming years, with great opportunities for the individual companies.Read
Commented by Stefan Feulner on June 1st, 2022 | 14:03 CEST
After the slump in biotech stocks - Bavarian Nordic, XPhyto and Evotec under review
Biotechnology experienced a boom in March 2020, when the world realized what biotech innovations could do to fight COVID-19. Investors pounced on the many promising technologies, driving up the stock prices of vaccine producers and making it easier for companies to raise capital for financing. However, since September of last year, the biotech sector has been on a steep downhill slide, at least on the stock market. The NASDAQ Biotechnology Index has lost more than 30% of its value since its high of 5,449.26 points until today. This drastic decline is reminiscent of the bursting of the bubble in the year 2000. But where are the opportunities now, and which stocks should investors rather refrain from investing in?Read
Commented by Carsten Mainitz on January 20th, 2022 | 12:14 CET
Evotec, Defence Therapeutics, Formycon - Who will benefit from Omicron?
The Coronavirus has shown that without biotechnology and ongoing research, we are relatively defenseless against the whims of nature. What would have happened if novel technology had not been available to produce potent vaccines in a very short time? Would our intensive care units have been as crowded as they were in Italy at the beginning of the pandemic? Would hospital triage be the norm today? No one can say for sure, but history has shown how epidemics - such as the Spanish flu - have claimed many lives in the past.Read